Bioabsorbable Stents (BAS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

BAS Pipeline Products Market Report Overview

Bioabsorbable stents are also known as bio-re-absorbable or biodegradable coronary stents. They are made from the material found in dissolvable sutures known as polylactic acid. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents. One unit refers to one bioabsorbable stent system.

The BAS pipeline market research report provides comprehensive information about the BAS pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

BAS Pipeline Products Market Segmentation by Territories

The key territories with products in the pipeline are the US, Europe, China, Australia, India, Japan, and Canada among others. As of April 2023, the US has the highest number of products in the pipeline out of them all.

BAS Pipeline Products Market Analysis, by Territories, 2023 (%)

BAS Pipeline Products Market Analysis, by Territories, 2023 (%)For more territory insights into the BAS pipeline products market, download a free report sample

BAS Pipeline Products Market Segmentation by Regulatory Paths

The key regulatory paths followed by the BAS pipeline products market are PMA, CE, NMPA, ICA, HSA, TGA, and MDL. Most of the products follow the PMA pathway to enter the market.

BAS Pipeline Products Market Analysis, by Regulatory Paths, 2023 (%)

BAS Pipeline Products Market Analysis, by Regulatory Paths, 2023 (%)

For more BAS pipeline products regulatory path insights, download a free report sample

BAS Pipeline Products Market - Competitive Landscape

Some of the leading companies in the BAS pipeline products market are Arterius Ltd, Biosensors International Group Ltd, Biosten, LLC, Biotronik AG, Biotronik SE & Co KG, Biotyx Medical (Shenzhen) Co Ltd, Boston Scientific Corp, Cardionovum GmbH, Cordis Corp, HangZhou HuaAn Biotechnology Co., Ltd., Icon Interventional Systems, Inc., Japan Stent Technology Co., Ltd., Kyoto Medical Planning Co Ltd among others.

For more company insights into the BAS pipeline products market, download a free report sample

BAS Pipeline Products Market Report Overview

Key Territories US, Europe, China, Australia, India, Japan, and Canada
Key Regulatory Paths PMA, CE, NMPA, ICA, HSA, TGA, and MDL
Leading Companies Arterius Ltd, Biosensors International Group Ltd, Biosten, LLC, Biotronik AG, Biotronik SE & Co KG, Biotyx Medical (Shenzhen) Co Ltd, Boston Scientific Corp, Cardionovum GmbH, Cordis Corp, HangZhou HuaAn Biotechnology Co., Ltd., Icon Interventional Systems, Inc., Japan Stent Technology Co., Ltd., Kyoto Medical Planning Co Ltd

Scope

This report provides an in-depth analysis of:

  • BAS under development
  • Details of major pipeline products which include product description, licensing and collaboration details, and other developmental activities
  • Major players involved in the development of BAS and lists all their pipeline projects
  • Pipeline products based on various stages of development ranging from early development to approved/issued stage
  • Key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage
  • Identify and understand important and diverse types of BAS under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date

Abbott Vascular Inc
Amaranth Medical Inc
Arterius Ltd
Biosensors International Group Ltd
Biosten, LLC
Biotronik AG
Biotronik SE & Co KG
Biotyx Medical (Shenzhen) Co Ltd
Boston Scientific Corp
Cardionovum GmbH
Cordis Corp
HangZhou HuaAn Biotechnology Co., Ltd.
Icon Interventional Systems, Inc.
Japan Stent Technology Co., Ltd.
Kyoto Medical Planning Co Ltd
Lifetech Scientific (Shenzhen) Co Ltd
Manli Cardiology Ltd
Meril Life Sciences Pvt Ltd
Micell Technologies Inc
Michigan Technological University
MicroPort Scientific Corp
Minvasys SAS
MIV Therapeutics Inc
NanoCoeur, Inc.
North Carolina State University
Northwestern University
OrbusNeich
Pediastent LLC
QualiMed Innovative Medizinprodukte GmbH
REVA Medical Inc
S3V Vascular Technologies
Shanghai Bio-heart Biological Technology Co Ltd
Shanghai Healing Medical Instruments Co Ltd
Tepha Inc
Tremedics Medical Devices LLC
UAB Minority Health and Health Equity Research Center
University of Florida
University of Strathclyde
VasoTech Inc.
Xenogenics Corporation

Table of Contents

  • 1 Table of Contents

    • 1.1 List of Tables
    • 1.2 List of Figures

  • 2 Introduction

    • 2.1 Bioabsorbable Stents (BAS) Overview

  • 3 Products under Development

    • 3.1 Bioabsorbable Stents (BAS) – Pipeline Products by Stage of Development
    • 3.2 Bioabsorbable Stents (BAS) – Pipeline Products by Territory
    • 3.3 Bioabsorbable Stents (BAS) – Pipeline Products by Regulatory Path
    • 3.4 Bioabsorbable Stents (BAS) – Pipeline Products by Estimated Approval Date
    • 3.5 Bioabsorbable Stents (BAS) – Ongoing Clinical Trials

  • 4 Bioabsorbable Stents (BAS) – Pipeline Products under Development by Companies

    • 4.1 Bioabsorbable Stents (BAS) Companies – Pipeline Products by Stage of Development
    • 4.2 Bioabsorbable Stents (BAS) – Pipeline Products by Stage of Development

  • 5 Bioabsorbable Stents (BAS) Companies and Product Overview

    • 5.1 Abbott Vascular Inc Company Overview

      • 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.2 Amaranth Medical Inc Company Overview

      • 5.2.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.3 Arterius Ltd Company Overview

      • 5.3.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.4 Biosensors International Group Ltd Company Overview

      • 5.4.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.5 Biosten, LLC Company Overview

      • 5.5.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.6 Biotronik AG Company Overview

      • 5.6.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview

    • 5.7 Biotronik SE & Co KG Company Overview

      • 5.7.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview

    • 5.8 Biotyx Medical (Shenzhen) Co Ltd Company Overview

      • 5.8.1 Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.9 Boston Scientific Corp Company Overview

      • 5.9.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.10 Cardionovum GmbH Company Overview

      • 5.10.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview

    • 5.11 Cordis Corp Company Overview

      • 5.11.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview

      • 5.12.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.13 Icon Interventional Systems, Inc. Company Overview

      • 5.13.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.14 Japan Stent Technology Co., Ltd. Company Overview

      • 5.14.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.15 Kyoto Medical Planning Co Ltd Company Overview

      • 5.15.1 Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.16 Lifetech Scientific (Shenzhen) Co Ltd Company Overview

      • 5.16.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.17 Manli Cardiology Ltd Company Overview

      • 5.17.1 Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.18 Meril Life Sciences Pvt Ltd Company Overview

      • 5.18.1 Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.19 Micell Technologies Inc Company Overview

      • 5.19.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.20 Michigan Technological University Company Overview

      • 5.20.1 Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview

    • 5.21 MicroPort Scientific Corp Company Overview

      • 5.21.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.22 Minvasys SAS Company Overview

      • 5.22.1 Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview

    • 5.23 MIV Therapeutics Inc Company Overview

      • 5.23.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.24 NanoCoeur, Inc. Company Overview

      • 5.24.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.25 North Carolina State University Company Overview

      • 5.25.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview

    • 5.26 Northwestern University Company Overview

      • 5.26.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview

    • 5.27 OrbusNeich Company Overview

      • 5.27.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview

    • 5.28 Pediastent LLC Company Overview

      • 5.28.1 Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.29 QualiMed Innovative Medizinprodukte GmbH Company Overview

      • 5.29.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview

    • 5.30 REVA Medical Inc Company Overview

      • 5.30.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.31 S3V Vascular Technologies Company Overview

      • 5.31.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview

    • 5.32 Shanghai Bio-heart Biological Technology Co Ltd Company Overview

      • 5.32.1 Shanghai Bio-heart Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.33 Shanghai Healing Medical Instruments Co Ltd Company Overview

      • 5.33.1 Shanghai Healing Medical Instruments Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.34 Tepha Inc Company Overview

      • 5.34.1 Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.35 Tremedics Medical Devices LLC Company Overview

      • 5.35.1 Tremedics Medical Devices LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.36 UAB Minority Health and Health Equity Research Center Company Overview

      • 5.36.1 UAB Minority Health and Health Equity Research Center Pipeline Products & Ongoing Clinical Trials Overview

    • 5.37 University of Florida Company Overview

      • 5.37.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview

    • 5.38 University of Strathclyde Company Overview

      • 5.38.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview

    • 5.39 VasoTech Inc. Company Overview

      • 5.39.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.40 Xenogenics Corporation Company Overview

      • 5.40.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview

  • 6 Bioabsorbable Stents (BAS)- Recent Developments

    • 6.1 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
    • 6.2 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023
    • 6.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022
    • 6.4 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022
    • 6.5 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule
    • 6.6 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022
    • 6.7 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022

  • 7 Appendix

    • 7.1 Methodology
    • 7.2 About GlobalData
    • 7.3 Contact Us
    • 7.4 Disclaimer

Frequently asked questions

Bioabsorbable Stents (BAS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Bioabsorbable Stents (BAS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bioabsorbable Stents (BAS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Bioabsorbable Stents (BAS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.